Search results
Results from the WOW.Com Content Network
Iodine-131 (131 I, I-131) is an important radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. [3] It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production.
Iodine-131 (131 I) is the most common RNT worldwide and uses the simple compound sodium iodide with a radioactive isotope of iodine. The patient (human or animal) may ingest an oral solid or liquid amount or receive an intravenous injection of a solution of the compound. The iodide ion is selectively taken up by the thyroid gland.
Radiation-induced thyroiditis is a form of painful, acute thyroiditis resulting from radioactive therapy to treat hyperthyroidism or from radiation to treat head and neck cancer or lymphoma. It affects 1% of those who have received radioactive iodine (I-131) therapy for Graves' Disease, typically presenting between 5 and 10 days after the ...
Radionuclide therapy (also known as systemic radioisotope therapy, radiopharmaceutical therapy, or molecular radiotherapy), is a form of targeted therapy. Targeting can be due to the chemical properties of the isotope such as radioiodine which is specifically absorbed by the thyroid gland a thousandfold better than other bodily organs.
Unlike the Wolff–Chaikoff effect, the Plummer effect does not prevent the thyroid from taking up radioactive iodine, e.g. in the case of nuclear emergencies.Therefore, "plummering" with high-dose iodine is only effective in a short time window after the release of radionuclides. [9]
Broad-spectrum empirical therapy (see below for choices) with high doses of one or more antibiotics should be initiated at the onset of fever. These antimicrobials should be directed at the eradication of Gram-negative aerobic organisms (i.e. Enterobacteriaceae, Pseudomonas ) that account for more than three-fourths of the isolates causing sepsis.
Iodine-123 (123 I) is a radioactive isotope of iodine used in nuclear medicine imaging, including single-photon emission computed tomography (SPECT) or SPECT/CT exams. The isotope's half-life is 13.2232 hours; [1] the decay by electron capture to tellurium-123 emits gamma radiation with a predominant energy of 159 keV (this is the gamma primarily used for imaging).
In some ways the Jod-Basedow phenomenon is the opposite of two physiological compensation mechanisms, the Plummer effect and the Wolff–Chaikoff effect, which in normal persons and in persons with thyroid disease, suppress the thyroid hormone after ingestion of large quantities of iodine or iodide. However, unlike the Plummer and Wolff ...